Search This Blog

Tuesday, January 1, 2019

119



This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.




Long live 2019!

by Charles-Edouard!

Until 2017, this blog has been collecting and offering available resources on alleviation in general with a focus on ICCARRE, Bitherapies and Mono-DTG. By excluding PI monotherapy, we had made the right choice. Dose reductions, such as A-TRI-WEEK or the half-pill, are of little interest: they are discussed episodically.

Mono-DTG has had its predictable setbacks and its quickest promoters (Bart Rijnders, Hocqueloux) have messed up the work: the Achilles Heel was a trap, they fell into it, head first, and Mono-DTG with them. This is very unfortunate... The Achilles Heel is very easy to avoid but very difficult to admit, especially since we have no simple explanatory mechanism or fine predictor. This leaves us with the only predictor being the therapeutic history of the host (the patient), without forgetting that we do not have the therapeutic history of the previous host.

We will therefore have two schools of thought, those of the usual barkers, who revile Mono-DTG, and those of the virologists (Katlama, Lanzafame, Ottenbuttel) who will manage, year after year, small cohorts totally dazzled by the genius of their prescriber, and stunned by the stupidity (or even the wickedness) of the medico-pharmaceutical underworld. Duly noted.



To ICCARRE, the Gold, to Mono-DTG, the Silver


Since we are dealing with both Mono-DTG and ICCARRE, it was appropriate to highlight the advantages of both. Apart from this blog, no one has taken care to elaborate on the Achilles heel, which puts us well above the pack, in terms of actual service to patients. By ratifying, as early as 2017, the 4/7, the Morlat report, made Quatuor obsolete, and even the official ICCARRE website, left in disarray. The official registration, which is hardly in doubt, at the end of Quatuor, puts an end to the militancy. We had asked the question frankly: does Morlat sign the end of this blog? He signed the end of his translation into Portuguese: our translator understood that it is only a matter of time that the practice of 4/7 percolates to Portugal or Brazil.

We have put online a Practical Guide to 4/7, as early as 2014, as well as a list of doctors: these are, by far, the 2 most downloaded documents, completely unpublished, at the price of minimal maintenance.

As for us, our development continues! We had set the bar quite high: the weekly intake, and beyond.

Now that the 4/7 is achieved, we have to do the same for the 1/7. There is a problem... The 4/7 is accessible to all, at the price of a simple verification on Genotype(and still... ), without distinguishing combinations, reservoirs and other nonsense, at one time agitated by Pr Rouzioux-des-fameux-critères, today put away in the attic. Read the Practical Guide, there is a good chance that you are eligible... But be sure to read it and discuss it with an ad hoc doctor, not just any doctor, please. Don't be fooled by charlatans of all kinds who seek the moral backing of the title of doctor to promote over-medication with invalidated efficacy.

The problem is that some combinations do not work after 3/7. If you are on a proven (Atripla, NVP/TDF/F-3TC) or favorable (Triumeq®) combination, you probably don't understand my concern. The risk is that experimenting without taking into account what we know, we could reproduce the unfortunate case of DOMONO and MONCAY, which would irreparably damage the 3/7. There are prohibited combinations (Kaletra, Isentress) and questionable combinations (probably Stribild®/Genvoya®). Therefore, as soon as there is a vote on a project, the whole clique votes against it and signals, in advance, its hostility. That's how you can recognize a false front.

2018: new concepts


A preliminary step will have been to develop our arguments by supporting them and preempting the usual objections: so we introduce new concepts:


- Eclipse equation (Pastor 05-2018)
- Dynamic remission (Pasteur 05-2018)
- Eclipse statistics (Pasteur 05-2018)
- Choke-and-mute (Pastor 05-2018)
- Distance to remission ( Salpêtrière 09-2018)
- Molecular synergies (Salpêtrière 09-2018, publication to come)
- OMNIBUS (Salpêtrière Sept. 2018)

At the end of 2018, there is a strong argument(the paradigm shift) for the OMNIBUS essays, now written and being refined. These concepts, well argued, are getting a very favorable reception and percolating very well in the all-Paris-that-counts. This is better than denouncing the professors, who are certainly suspected of collusion... Quatuor has put them out of the running.

2018: New tools


As of 2018, we have a modern tool that was previously reserved for professionals: audio-visual presentations. We have taken a cue from the École Normale Supérieure and extended the tool to YouTube portability. Our YouTube channel is starting and 2019 should have a good dozen new presentations.

OMNIBUS is probably the most exciting thing I did in 2018. The website dedicated to it is being tested, it will be available soon...

The trip to Lourdes


The trip to Lourdes? It is the strategy that signs the absence of strategy. Wishful thinking is not a strategy, intermittence is...

This is the main difference between intermittency and lightening: intermittency reduces the active reservoir: this is the choke-and-mute mechanism. The analogy of the lid on the kettle, made popular by Prof. Rouzioux-of-famous-criteria-is-defective, is a deception. No! When you open the lid, the steam does not come out immediately: this is not true.

We don't know how to wake up the tank! However, it inevitably wakes up. So, if you don't know how to wake up the tank, why don't you let it wake up by itself, a little bit, and then slap it in the face and do it again, until you run out. That's a strategy, and we know it works.

The problem goes further: we don't have a remission strategy (although we know, since the Berlin patient, that it is possible) and we don't have an eradication strategy, although we know, since smallpox, that it is possible, or even almost possible for polio, or even, with a little more effort, tuberculosis. We have no strategy to lower the cost, except to relocate jobs to India or China (Bravo!).

Omnibus


Omnibus moves forward... The documentation needed for the OMNIBUS-3D test is written. I let it rest for a while, just to breathe, and I start OMNIBUS-Bicycle.

In the news


- Homeopathy: we finally address the fundamental question: why reimburse a useless 'drug'? The same question will be asked at the end of Quatuor: explain why we have to reimburse the 7/7, which we now know that 3 doses out of 7 are without therapeutic benefit.

- I have added a comparative table to my post on the new dual therapies (see also the discussions in comments)

The genius in video


I'm reposting here links to 2 videos that I find very inspiring: Pr Schinadzi 's (inventor of F-3TC and the HCV cure) and Dr A. Faucy 's on broad spectrum antibodies.

Feel free to comment, like, share and use

good weekend, good stuffing and not too many meds ... Huh?